Shaily Engineering Plastics (501423) Q4 25/26 earnings summary

Executive summary

• Navigated Q4 FY 2026 amid geopolitical uncertainty, supply chain disruptions, and raw material inflation, leveraging a diversified customer base and disciplined execution.

• Achieved strong revenue growth of 26% year-over-year to ₹990.7 crore on a consolidated basis for FY26, driven by healthcare segment expansion and new business wins, including commercial launches of pen injectors for semaglutide in India, Canada, and tentative approval in the U.S.

• Entered the consumer electronics and semiconductor supply chains, signing a key agreement with a Korean company for semiconductor trays.

• Board approved an enabling resolution to raise up to INR 500 crores (₹500 crore) annually for financial flexibility and growth opportunities.

• Strengthened operations with the onboarding of a new COO for healthcare.

Financial highlights

• FY 2026 consolidated revenue grew 26% year-on-year to INR 991 crores (₹990.7 crore); Q4 revenue up 9% to INR 237 crores (₹236.8 crore).

• EBITDA increased 61% year-on-year to INR 288 crores (₹287.7 crore) with margins at 29–29.3%.

• PAT surged 83% to INR 170 crores (₹169.9 crore); PAT margin at 17.2%.

• Cash PAT for FY 2026 at INR 219 crores (₹219.1 crore), up 62% year-on-year.

• Standalone revenue up 25% to ₹921.2 crore; standalone PAT up 128% to ₹161.3 crore.

Outlook and guidance

• Priorities for FY 2027 include scaling healthcare, building the Abu Dhabi facility, deepening consumer electronics and semiconductor programs, and restoring growth in consumer home furnishings.

• Confident in sustaining and improving margins year-on-year, with capacity ramp-up expected to drive growth.

• Projected pen injector production of 36–40 million units in FY 2027, targeting 50 million the following year.

• Board recommended a dividend of ₹3 (150%) per fully paid equity share for FY26, subject to shareholder approval.